Get the Stockscreener App
7.25
0.55%
-0.04
After Hours:
7.38
0.13
+1.79%
Precision Biosciences Inc stock is traded at $7.25, with a volume of 250.61K.
It is down -0.55% in the last 24 hours and down -0.55% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$7.29
Open:
$7.29
24h Volume:
250.61K
Relative Volume:
0.62
Market Cap:
$187.07M
Revenue:
$45.07M
Net Income/Loss:
$-44.49M
P/E Ratio:
-1.951
EPS:
-3.716
Net Cash Flow:
$-54.23M
1W Performance:
-1.49%
1M Performance:
-0.55%
6M Performance:
+75.54%
1Y Performance:
+40.78%
1-Day Range:
$7.21
$7.73
1-Week Range:
$7.07
$7.73
52-Week Range:
$3.53
$9.62
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.25 | 188.10M | 45.07M | -44.49M | -54.23M | -3.716 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences Inc (DTIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision BioSciences Inc (DTIL) Income Statement - TradingKey
Precision BioSciences (DTIL) Announces Leadership Restructuring for Clinical Development - GuruFocus
Precision BioSciences Announces Executive Leadership Changes to Advance Gene Editing Programs - Minichart
Precision Biosciences, Inc. Announces Chief Financial Officer Changes, Effective August 1, 2026 - marketscreener.com
Precision BioSciences Announces Key Executive Leadership Changes - TipRanks
Precision BioSciences (DTIL) Announces Leadership Changes - GuruFocus
Precision BioSciences appoints Alex Kelly COO; Naresh Tanna named CFO - TradingView
Precision BioSciences announces leadership changes - Investing.com
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones - Business Wire
DTIL|Precision BioSciences Inc|Price:7.240|Chg%:-0.050 - TradingKey
Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DTIL|Precision BioSciences Inc|Price:7.290|Chg%:-0.040 - TradingKey
Lynx1 Capital Management LP Acquires Additional Shares in Precis - GuruFocus
Precision BioSciences Inc (DTIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision BioSciences (DTIL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline - dars.gov.et
Precision BioSciences (DTIL) Rallies 3.5% as Biotech Stock Tests Key Resistance LevelCovered Call Trade - dars.gov.et
Lynx1 Capital discloses 5.4% Precision BioSciences (DTIL) ownership in Schedule 13G - Stock Titan
Trading the Move, Not the Narrative: (DTIL) Edition - Stock Traders Daily
Precision BioSciences (DTIL) Proxy filing Summary - Quartr
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Grants Stock Units to New Employees Amid G - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 - BioSpace
Precision BioSciences (DTIL) Grants Inducement Awards to New Hir - GuruFocus
Precision BioSciences (DTIL) Slips 4.4% as Stock Tests Key Support LevelsPercent Above MA - dars.gov.et
Precision BioSciences, Inc. Actuals & Estimates (TRADEGATE:PBS0) - TradingView
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? - Yahoo Finance
Enterprise value to revenue forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Updates Investors with Latest Corporate Deck in July 2026 SEC 8-K Filing - Minichart
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B - TipRanks
Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timeline - Stock Titan
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Index - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Value Benchmark - marketscreener.com
Precision BioSciences added to Russell 2000 index By Investing.com - Investing.com Nigeria
Precision BioSciences added to Russell 2000 index - Investing.com
Precision BioSciences (DTIL) Joins Russell 2000 Index, Highlighting Growth Potential - GuruFocus
Index Expanding Market Visibility with Institutional Investors - Business Wire
Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Dynamic Index - marketscreener.com
Precision BioSciences, Inc. Actuals & Estimates (DUS:PBS0) - TradingView
Price to sales forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Inc (DTIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to earnings forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences, Inc. Actuals & Estimates (NASDAQ:DTIL) - TradingView
Enterprise value to EBIT forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
Enterprise value to revenue forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
DTIL Forecast — Price Target — Prediction for 2027 - TradingView
Precision BioSciences earnings calendar and gene-editing focus, shares remain a small-cap biotech pl - AD HOC NEWS
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):